Literature DB >> 15550517

mitoKATP channel activation in the postanoxic developing heart protects E-C coupling via NO-, ROS-, and PKC-dependent pathways.

Alexandre Sarre1, Norbert Lange, Pavel Kucera, Eric Raddatz.   

Abstract

Whereas previous studies have shown that opening of the mitochondrial ATP-sensitive K(+) (mitoK(ATP)) channel protects the adult heart against ischemia-reperfusion injury, it remains to be established whether this mechanism also operates in the developing heart. Isolated spontaneously beating hearts from 4-day-old chick embryos were subjected to 30 min of anoxia followed by 60 min of reoxygenation. The chrono-, dromo-, and inotropic disturbances, as well as alterations of the electromechanical delay (EMD), reflecting excitation-contraction (E-C) coupling, were investigated. Production of reactive oxygen species (ROS) in the ventricle was determined using the intracellular fluorescent probe 2',7'-dichlorofluorescin (DCFH). Effects of the specific mitoK(ATP) channel opener diazoxide (Diazo, 50 microM) or the blocker 5-hydroxydecanoate (5-HD, 500 microM), the nitric oxide synthase (NOS) inhibitor N(G)-nitro-L-arginine methyl ester (L-NAME, 50 microM), the antioxidant N-(2-mercaptopropionyl)glycine (MPG, 1 mM), and the PKC inhibitor chelerythrine (Chel, 5 microM) on oxidative stress and postanoxic functional recovery were determined. Under normoxia, the baseline parameters were not altered by any of these pharmacological agents, alone or in combination. During the first 20 min of postanoxic reoxygenation, Diazo doubled the peak of ROS production and, interestingly, accelerated recovery of ventricular EMD and the PR interval. Diazo-induced ROS production was suppressed by 5-HD, MPG, or L-NAME, but not by Chel. Protection of ventricular EMD by Diazo was abolished by 5-HD, MPG, L-NAME, or Chel, whereas protection of the PR interval was abolished by L-NAME exclusively. Thus pharmacological opening of the mitoK(ATP) channel selectively improves postanoxic recovery of cell-to-cell communication and ventricular E-C coupling. Although the NO-, ROS-, and PKC-dependent pathways also seem to be involved in this cardioprotection, their interrelation in the developing heart can differ markedly from that in the adult myocardium.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15550517     DOI: 10.1152/ajpheart.00942.2004

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  6 in total

Review 1.  Physiology of potassium channels in the inner membrane of mitochondria.

Authors:  Ildikò Szabò; Luigi Leanza; Erich Gulbins; Mario Zoratti
Journal:  Pflugers Arch       Date:  2011-11-18       Impact factor: 3.657

2.  Transient anoxia and oxyradicals induce a region-specific activation of MAPKs in the embryonic heart.

Authors:  Stephany Gardier; Sarah Pedretti; Alexandre Sarre; Eric Raddatz
Journal:  Mol Cell Biochem       Date:  2010-03-21       Impact factor: 3.396

3.  Modulation of the c-Jun N-terminal kinase activity in the embryonic heart in response to anoxia-reoxygenation: involvement of the Ca2+ and mitoKATP channels.

Authors:  Alexandre Sarre; Stéphany Gardier; Fabienne Maurer; Christophe Bonny; Eric Raddatz
Journal:  Mol Cell Biochem       Date:  2008-04-17       Impact factor: 3.396

4.  Regulatory role of mitochondria in oxidative stress and atherosclerosis.

Authors:  Jui-Chih Chang; Shou-Jen Kou; Wei-Ting Lin; Chin-San Liu
Journal:  World J Cardiol       Date:  2010-06-26

5.  What Is the Optimal Light Source for Optical Mapping Using Voltage- and Calcium-Sensitive Dyes?

Authors:  V Olejnickova; D Sedmera
Journal:  Physiol Res       Date:  2020-06-25       Impact factor: 1.881

6.  Glibenclamide inhibits BK polyomavirus infection in kidney cells through CFTR blockade.

Authors:  Margarita-Maria Panou; Michelle Antoni; Ethan L Morgan; Eleni-Anna Loundras; Christopher W Wasson; Matthew Welberry-Smith; Jamel Mankouri; Andrew Macdonald
Journal:  Antiviral Res       Date:  2020-03-27       Impact factor: 5.970

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.